Selected publications from the Malmberg lab

A complete publication list can be found here (PubMed)

2022

  1. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.
    Hammer Q, Dunst J, Christ W, Picarazzi F, Wendorff M, Momayyezi P, Huhn O, Netskar HK, Maleki KT, García M, Sekine T, Sohlberg E, Azzimato V, Aouadi M, , , Degenhardt F, Franke A, Spallotta F, Mori M, Michaëlsson J, Björkström NK, Rückert T, Romagnani C, Horowitz A, Klingström J, Ljunggren HG, Malmberg KJ Cell Rep 2022 03;38(10):110503 
    PMID: 35235832 PMCID: PMC8858686 DOI: 10.1016/j.celrep.2022.110503
     
  2. Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia.
    Sohlberg E, Pfefferle A, Heggernes Ask E, Tschan-Plessl A, Jacobs B, Netskar H, Lorenz S, Kanaya M, Kosugi-Kanaya M, Meinke S, Mörtberg A, Höglund P, Sundin M, Carlsson G, Palmblad J, Malmberg KJ
    Blood 2022 02;139(5):704-716 
    PMID: 34699594 DOI: 10.1182/blood.2021013233

2021

  1. Advances in immune therapies in hematological malignancies.
    Mazzarella L, Enblad G, Olweus J, Malmberg KJ, Jerkeman M, J Intern Med 2021 Oct;(): PMID:34624160
     
  2. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
    Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, Tuininga K, Zhang B, Wu CY, Kodal B, Khaw M, Bendzick L, Rogers P, Ge MQ, Bonello G, Meza M, Felices M, Huffman J, Dailey T, Lee TT, Walcheck B, Malmberg KJ, Blazar BR, Bryceson YT, Valamehr B, Miller JS, Cichocki F, Cell Stem Cell 2021 Sep;(): PMID34525347
     
  3. Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K, Vallera DA, Lee T, Bjordahl R, Malmberg KJ, Valamehr B, Miller JS, Mol Ther 2021 Dec;29(12):3410-3421 PMID: 34174441
     
  4. Natural killer cell receptors regulate responses of HLA-E-restricted T cells.
    Sullivan LC, Nguyen THO, Harpur CM, Stankovic S, Kanagarajah AR, Koutsakos M, Saunders PM, Cai Z, Gray JA, Widjaja JML, Lin J, Pietra G, Mingari MC, Moretta L, Samir J, Luciani F, Westall GP, Malmberg KJ, Kedzierska K, Brooks AG, Sci Immunol 2021 Apr;6(58): PMID: 33893172

2020

  1. Deciphering Natural Killer Cell Homeostasis.
    Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg KJ
    Front Immunol 2020 ;11():812
     
  2. TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells.
    Clement D, Goodridge JP, Grimm C, Patel S, Malmberg KJ
    Front Immunol 2020 ;11():753
     
  3. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
    Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al
    Cell Stem Cell 2020 Jun;():
     
  4. Natural killer cell immunotypes related to COVID-19 disease severity.
    Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, et al
    Sci Immunol 2020 08;5(50):

2019

  1. Remodeling of secretory lysosomes during education tunes functional potential in NK cells.
    Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, et al
    Nat Commun 2019 01;10(1):514
     
  2. Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity.
    Pfefferle A, Jacobs B, Netskar H, Ask EH, Lorenz S, Clancy T, et al
    Cell Rep 2019 Nov;29(8):2284-2294.e4
     
  3. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
    Enqvist M, Jacobs B, Junlén HR, Schaffer M, Melén CM, Friberg D, et al
    Front Immunol 2019 ;10():2085
     
  4. Induction of the BIM Short Splice Variant Sensitizes Proliferating NK Cells to IL-15 Withdrawal.
    Jacobs B, Pfefferle A, Clement D, Berg-Larsen A, Saetersmoen ML, Lorenz S, et al
    J. Immunol. 2019 02;202(3):736-746
     
  5. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ
    Semin Immunopathol 2019 01;41(1):59-68

2018

  1. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
    Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al
    Clin. Cancer Res. 2018 04;24(8):1834-1844
     
  2. Induction of the BIM Short Splice Variant Sensitizes Proliferating NK Cells to IL-15 Withdrawal.
    Jacobs B, Pfefferle A, Clement D, Berg-Larsen A, Saetersmoen ML, Lorenz S, et al
    J. Immunol. 2019 02;202(3):736-746
     
  3. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, et al
    Cancer Immunol Res 2018 04;6(4):467-480
     
  4. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ
    Semin Immunopathol 2019 01;41(1):59-68
     
  5. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
    De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, et al
    Cytokine Growth Factor Rev. 2018 12;44():1-10

2017

  1. Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.
    Liu LL, Béziat V, Oei VYS, Pfefferle A, Schaffer M, Lehmann S, et al
    Cancer Immunol Res 2017 08;5(8):654-665
     
  2. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren HG
    Semin. Immunol. 2017 06;31():20-29
     
  3. Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.
    Malmberg KJ, Sohlberg E, Goodridge JP, Ljunggren HG
    Immunogenetics 2017 08;69(8-9):547-556
     
  4. Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery.
    Clancy T, Dannenfelser R, Troyanskaya O, Malmberg KJ, Hovig E, Kristensen V
    Curr. Pharm. Des. 2017 ;23(32):4716-4725
     
  5. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
    Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, et al
    J. Clin. Invest. 2017 Nov;127(11):4042-405

2016

  1. Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans.
    Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, et al
    Cell Rep 2016 05;15(5):1088-1099
     
  2. Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Björklund AT, Clancy T, Goodridge JP, Béziat V, Schaffer M, Hovig E, et al
    J. Immunol. 2016 Feb;196(3):1400-11
     
  3. Class I HLA haplotypes form two schools that educate NK cells in different ways.
    Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, Béziat V, et al
    Sci Immunol 2016 09;1(3):
     
  4. Cognate HLA absence in trans diminishes human NK cell education.
    Landtwing V, Raykova A, Pezzino G, Béziat V, Marcenaro E, Graf C, et al
    J. Clin. Invest. 2016 10;126(10):3772-3782
     
  5. Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.
    Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, et al
    Oncoimmunology 2016 May;5(5):e1138199

2015

  1. Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients.
    Béziat V, Sleiman M, Goodridge JP, Kaarbø M, Liu LL, Rollag H, et al
    Front Immunol 2015 ;6():507
     
  2. Coordinated expression of DNAM-1 and LFA-1 in educated NK cells.
    Enqvist M, Ask EH, Forslund E, Carlsten M, Abrahamsen G, Béziat V, et al
    J. Immunol. 2015 May;194(9):4518-27
     
  3. Newtonian cell interactions shape natural killer cell education.
    Goodridge JP, Önfelt B, Malmberg KJ
    Immunol. Rev. 2015 Sep;267(1):197-213
     
  4. Harnessing adaptive natural killer cells in cancer immunotherapy.
    Liu LL, Pfefferle A, Yi Sheng VO, Björklund AT, Béziat V, Goodridge JP, et al
    Mol Oncol 2015 Dec;9(10):1904-17
     
  5. Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.
    Sohlberg E, Pfefferle A, Andersson S, Baumann BC, Hellström-Lindberg E, Malmberg KJ
    Oncotarget 2015 Oct;6(33):34178-90